Clinical trials: Advanced Solid Tumor, Adult
Adult
GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors
This study is a single center, single arm phase I clinical trial. This study proposes to enroll 20 subjects, with a trial protocol including chemotherapy pretreatment, reinfusion of autologous tumor infiltrating lymphocyte…
- Trial name
- NCT06077903
- Testing
- GT101
- Volunteers
- 10 people
- Sponsor
- Grit Biotechnology
Non-Small Cell Lung Cancer, NSCLC
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors.
- Conditions
- Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer)
- Trial name
- NCT06917079
- Testing
- BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin)
- Where
- 17 sites in United States, Australia
- Volunteers
- 665 people
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Advanced Solid Tumors
AMG 386 Drug-Drug Interaction Study With Paclitaxel
The purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone and in combination with AMG 386 to determine whether AMG 386 alters the pharmacokinetics of paclitaxel
- Trial name
- NCT01992341
- Testing
- AMG 386, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Amgen
Adult Solid Tumor
Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of HLX26 and HLX10 in Patients With Advanced/Metastatic Solid Tumor
This study is a open-label, phase I, dose escalation clinical study to evaluate the safety and tolerability of HLX26 and HLX10 in the treatment of patients with advanced/metastatic solid tumors.
- Trial name
- NCT05400265
- Testing
- HLX26, HLX10
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai Henlius Biotech
Breast Cancer, Solid Tumor, Adult
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
This is a multi-center, open-label, phase Ib/II study of APG-2575 as a single agent in patients with advanced solid tumors or in combination with anti-cancer agents such as CDK 4/6 inhibitor palbociclib in patients with ER+/HER2…
- Trial name
- NCT04946864
- Testing
- APG-2575, Palbociclib
- Where
- 7 sites in United States, China
- Volunteers
- 65 people
- Sponsor
- Ascentage Pharma Group Inc.
Solid Tumor
Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion
This is a Phase 1, open-label, multicenter, dose escalation and expansion study of the safety, PK, PD, and preliminary anti-tumor activity of IDE397 as a single agent and in combination with sacituzumab govitecan (SG), in adult…
- Trial name
- NCT04794699
- Testing
- IDE397, Sacituzumab govitecan
- Where
- 37 sites in United States, Australia and 5 more
- Volunteers
- 169 people
- Sponsor
- IDEAYA Biosciences
Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors
SI-B036-ST-101 in Advanced/Metastatic Solid Tumors
The objective of the study is to evaluate the safety and tolerability of SI-B036 in participants with solid tumors who have received at least one prior line of therapy for advanced disease.
- Conditions
- Locally Advanced /Metastatic Solid Tumors, Locally Advanced / Metastatic Solid Tumors, Metastatic Solid Cancers, Non Small Cell Lung Cancer
- Trial name
- NCT07857616
- Testing
- SI-B036
- Where
- 7 sites in United States
- Volunteers
- 424 people
- Sponsor
- SystImmune Inc.
Advanced Solid Tumors
A Study of ASP1002 in Adults for Treatment of Solid Tumors
ASP1002 is being studied in people with tumors that have spread to nearby tissue (locally advanced) that cannot be removed by surgery (unresectable) or tumors that have spread to other parts of the body (metastatic).
- Trial name
- NCT05719558
- Testing
- ASP1002, Bevacizumab, Oxaliplatin
- Where
- 15 sites in United States
- Volunteers
- 798 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Advanced Solid Tumor, Soft Tissue Sarcoma Adult
Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors
This is a Phase 1, first-in-human, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 administered to patients with advanced solid tumors.
- Trial name
- NCT05352750
- Testing
- SON-1010
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Sonnet BioTherapeutics
Solid Tumor, Adult, Lymphoma
A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma
This study is a first-in-class open-label phase I human clinical study to evaluate the safety and tolerability of HLX26 with escalated doses in the treatment of patients with advanced/metastatic solid tumors or lymphomas.
- Trial name
- NCT05078593
- Testing
- HLX26
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Shanghai Henlius Biotech
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES)
- Trial name
- TRuST (NCT02875548)
- Testing
- Tazemetostat
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Epizyme, Inc.
Cancer, Advanced Solid Tumors
A Study of BBI608 and BBI503 Administered in Combination to Adult Patients With Advanced Solid Tumors
This is an open label, multi-center, phase 1 study of BBI608 and BBI503 administered orally in combination to patients with advanced solid tumors.
- Trial name
- NCT02432326
- Testing
- BBI608, BBI503
- Where
- 11 sites in United States
- Volunteers
- 147 people
- Sponsor
- Sumitomo Pharma America, Inc.
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Lung Cancer, Non-small Cell, Lung Cancer Metastatic
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
The Sponsor is developing KB707, a replication-defective, non-integrating herpes simplex virus type 1 (HSV-1)-derived vector designed to stimulate an anti-tumor immune response through the production of cytokines within the local…
- Conditions
- Lung Cancer, Non-small Cell, Lung Cancer Metastatic, Solid Tumor, Adult, Advanced Cancer
- Trial name
- KYANITE-1 (NCT06228326)
- Testing
- KB707, Pembrolizumab (KEYTRUDA®), Chemotherapy
- Where
- 14 sites in United States
- Volunteers
- 250 people
- Sponsor
- Krystal Biotech, Inc.
Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P02 as a monotherapy or in…
- Conditions
- Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
- Trial name
- NCT06747585
- Testing
- ALE.P02, Pembrolizumab
- Where
- 41 sites in United States, France and 6 more
- Volunteers
- 235 people
- Sponsor
- Alentis Therapeutics AG
Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric
Clofarabine in Adult Patients With Advanced Solid Tumors
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment…
- Conditions
- Solid Tumors, Leukemia, Lymphocytic, Acute, Pediatric, Leukemia, Lymphocytic, Acute, Adult, Leukemia, Myelocytic, Acute, Pediatric
- Trial name
- NCT00125840
- Testing
- clofarabine (IV formulation)
- Where
- 2 sites in United States
- Sponsor
- Genzyme, a Sanofi Company
Advanced Solid Tumors
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy.
- Trial name
- COMBINE-EGFR-1 (NCT04626635)
- Testing
- REGN7075, Cemiplimab, Platinum-based doublet chemotherapy
- Where
- 54 sites in United States, France and 5 more
- Volunteers
- 548 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumors, Adult
Study of ON 123300 in Patients With Advanced Cancer
This study will investigate the safety of the drug ON 123300 at increasing doses to determine the best dose to use in future clinical trials.
- Trial name
- NCT04739293
- Testing
- ON123300
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Traws Pharma, Inc.
Solid Tumor, Adult
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
This Phase 1/2, first-in-human, open-label, multicenter study follows a 3+3 ascending dose escalation design to determine the MTD/RP2D and to characterize the safety, tolerability, PK, and antitumor effects of LNS8801 alone and…
- Trial name
- NCT04130516
- Testing
- LNS8801 -Small molecule, orally bioavailable, selective agonist of GPER, Pembrolizumab - anti-PD-1 antibody
- Where
- 10 sites in United States
- Volunteers
- 200 people
- Sponsor
- Linnaeus Therapeutics, Inc.
Solid Tumors, Adult
A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors
This is a first-in-human (FIH), phase Ⅰ/Ⅱa, open-label, multicenter clinical study of HMPL-A251 monotherapy in adult participants with unresectable, advanced or metastatic HER2-expressing solid tumors.
- Trial name
- NCT07228247
- Testing
- HMPL-A251
- Where
- 15 sites in United States, China
- Volunteers
- 147 people
- Sponsor
- Hutchmed